Session Information
-
WCLC 2019
2019 World Conference on Lung Cancer
Conference Program for the 2019 World Conference on Lung Cancer in Barcelona, Spain
Presentation Date(s):- Sept 7 - 10, 2019
- Total Presentations: 2970
September 7 Sat
Sep 7 Sunday
September 8 Sun
Sep 8 Monday
September 9 Mon
Sep 9 Tuesday
September 10 Tue
Sep 10
-
+
IS02 - Symposium by Ology Medical Education: Spotlight On Emerging Immunotherapy Approaches And MET Inhibitors In Advanced NSCLC (Not IASLC CME Accredited)
- 11:30 - 13:00
- 9/07/2019
- Location: Hilton Head (1978)
- Type: Industry Symposia & Workshops
- Track:
-
+
YI04 - Basics of Immunology
- 13:30 - 15:00
- 9/08/2019
- Location: Dublin (1997)
- IASLC CME Accredited
- Type: Young Investigator Session
- Track: Young Investigators
- Moderators:Noemi Reguart, Julie R Brahmer
-
+
YI04.02 - Immuno-Oncology Trials: Other Endpoints Needed?
13:50 - 14:10 | Presenter: Martin Reck
- Abstract
Loading...
-
+
MA08 - Pawing the Way to Improve Outcomes in Stage III NSCLC
- 15:15 - 16:45
- 9/08/2019
- Location: Tokyo (1982)
- IASLC CME Accredited
- Type: Mini Oral Session
- Track: Treatment of Locoregional Disease - NSCLC
- Moderators:Simon Ekman, Helena A Yu
-
+
MA08.02 - Durvalumab Impact in the Treatment Strategy of Stage III Non-Small Cell Lung Cancer (NSCLC): An EORTC Young Investigator Lung Cancer Group Survey
15:20 - 15:25 | Presenter: Matteo Giaj Levra | Author(s): Justin Benet, Baktiar Hasan, Thierry Berghmans, Alessio Bruni, Anne Marie Clasina Dingemans, Niccolo' Giaj Levra, John G Edwards, Corinne Faivre-Finn, Nicolas Girard, Elisa Gobbini, Laurent Greillier, Lizza Hendriks, Sylvie Lantuejoul, Antonin Levy, Silvia Novello, Mary O'Brien, Martin Reck, Alessia Pochesci, Jessica Menis, Benjamin Besse
- Abstract
Loading...
-
+
OA04 - Immuno Combinations and the Role of TMB
- 15:15 - 16:45
- 9/08/2019
- Location: Copenhagen (1980)
- IASLC CME Accredited
- Type: Oral Session
- Track: Immuno-oncology
- Moderators:Solange Peters, Martin Reck
-
+
OA04.01 - A Phase III Randomized Study of Nivolumab/Ipilimumab vs Nivolumab for Previously Treated Stage IV Squamous Cell Lung Cancer
15:15 - 15:25 | Presenter: Lyudmila Bazhenova | Author(s): Mary Redman, Scott Gettinger, Fred R. Hirsch, Philip Mack, Lawrence H Schwartz, David R Gandara, Jeffrey D Bradley, Thomas Stinchcombe, Natasha B Leighl, Suresh S Ramalingam, Susan Tavernier, Katherine Minichiello, Karen Kelly, Vassiliki A Papadimitrakopoulou, Roy S. Herbst
- Abstract
Loading... -
+
OA04.02 - CheckMate 817: First-Line Nivolumab + Ipilimumab in Patients with ECOG PS 2 and Other Special Populations with Advanced NSCLC
15:25 - 15:35 | Presenter: Fabrice Barlesi | Author(s): Clarisse Audigier-Valette, Enriqueta Felip, Tudor-Eliade Ciuleanu, Kevin Jao, Erika Rijavec, Laszlo Urban, Jean-Sébastien Aucoin, Cristina Zannori, Karim Vermaelen, Osvaldo Aren Frontera, Neal Ready, Alessandra Curioni Fontecedro, Helena Linardou, Elena Poddubskaya, Jürgen R. Fischer, Ingrid Iordan, Harry JM Groen, Rathi N Pillai, Sunney Li, Joseph Fiore, Han Chang, Angelic Acevedo, Luis Paz-Ares
- Abstract
Loading... -
+
OA04.03 - A Randomized Phase 3 Study of Camrelizumab plus Chemotherapy as 1st Line Therapy for Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer
15:35 - 15:45 | Presenter: Caicun Zhou | Author(s): Gongyan Chen, yunchao Huang, Jianying Zhou, LiZhu Lin, Jifeng Feng, Zhehai Wang, Yongqian Shu, Jianhua Shi, Yi Hu, Qiming Wang, Ying Cheng, Jianhua Chen, Xiaoyan Lin, Yongsheng Wang, Jianan Huang, Jiuwei Cui, Lejie Cao, Yunpeng Liu, Yiping Zhang, Yueyin Pan, Jun Zhao, LiPing Wang, Jianhua Chang, Qun Chen, Xiubao Ren, Wei Zhang, Yun Fan, Zhiyong He, Jian Fang, Kangsheng Gu, Xiaorong Dong, Faguang Jin, Hongjun Gao, Guangyu An, Cuimin Ding, Xiaodong Jiang, Jianping Xiong, Xiangdong Zhou, Sheng Hu, Ping Lu, Anwen Liu, Shuliang Guo, Jianjin Huang, Chengchu Zhu, Jian Zhao, Beili Gao, Yinglan Chen, Chengping Hu, Jian Zhang, Hongmei Zhang, Hui Zhao, Yujie Zhou, Yanfei Tai
- Abstract
Loading... -
+
OA04.04 - Discussant - OA04.01, OA04.02, OA4.03
15:45 - 16:00 | Presenter: Martin Sebastian
- Abstract
No abstract available for this presentation
-
+
OA04.05 - KEYNOTE-021: TMB and Outcomes for Carboplatin and Pemetrexed With or Without Pembrolizumab for Nonsquamous NSCLC
16:00 - 16:10 | Presenter: Corey Jay Langer | Author(s): Shirish Gadgeel, Hossein Borghaei, Amita Patnaik, Steven F. Powell, Ryan D Gentzler, James Chih-Hsin Yang, Matthew A. Gubens, Lecia Sequist, Mark Awad, Razvan Cristescu, Deepti Aurora-Garg, Andrew Albright, Andrey Loboda, Julie Kobie, Jared K. Lunceford, Mark Ayers, Gregory M Lubiniecki, Bilal Piperdi, M. Catherine Pietanza, Vassiliki A Papadimitrakopoulou
- Abstract
Loading... -
+
OA04.06 - Evaluation of TMB in KEYNOTE-189: Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy for Nonsquamous NSCLC
16:10 - 16:20 | Presenter: Marina Chiara Garassino | Author(s): Delvys Rodriguez-Abreu, Shirish Gadgeel, Emilio Esteban, Enriqueta Felip, Giovanna Speranza, Martin Reck, Rina Hui, Michael Boyer, Razvan Cristescu, Deepti Aurora-Garg, Andrew Albright, Andrey Loboda, Julie Kobie, Jared K. Lunceford, Mark Ayers, Gregory M Lubiniecki, Bilal Piperdi, M. Catherine Pietanza, Edward Garon
- Abstract
Loading... -
+
OA04.07 - Mutations Associated with Sensitivity or Resistance to Immunotherapy in mNSCLC: Analysis from the MYSTIC Trial
16:20 - 16:30 | Presenter: Naiyer A Rizvi | Author(s): Byoung Chul Cho, Niels Reinmuth, Ki Hyeong Lee, Alexander Luft, Myung-Ju Ahn, Vassiliki A Papadimitrakopoulou, John Victor Heymach, Urban Scheuring, Brandon Higgs, Jiabu Ye, Michael Kuziora, Song Wu, Feng Liu, Han Si, Solange Peters
- Abstract
Loading... -
+
OA04.08 - Discussant - OA04.05, OA04.06, OA4.07
16:30 - 16:45 | Presenter: Melissa Johnson
- Abstract
No abstract available for this presentation
-
+
P1.01 - Advanced NSCLC
- 09:45 - 18:00
- 9/08/2019
- Location: Exhibit Hall
- Type: Poster Viewing in the Exhibit Hall
- Track: Advanced NSCLC
-
+
P1.01-108 - PACIFIC-6: A Phase II Study of Durvalumab Following Sequential Chemoradiotherapy in Patients with Stage III, Unresectable NSCLC
09:45 - 09:45 | Presenter: Marina Chiara Garassino | Author(s): Corinne Faivre-Finn, Julien Mazieres, Martin Reck, Ugochi Emeribe, April Franks, Nataliya Trunova
- Abstract
Loading... -
+
P1.01-110 - Novel Regimens Versus Standard-of-Care in NSCLC: A Phase II, Randomized, Open-Label, Platform Trial Using a Master Protocol
09:45 - 09:45 | Presenter: David R Spigel | Author(s): Marina Chiara Garassino, Benjamin Besse, Adrian Sacher, Minal Barve, Sophie Cousin, Michael Schenker, Debra Rogan, Sapna Yadavilli, Andre Acusta, Ohad Amit, Ann Leighton-Swayze, Marc Ballas, Axel Hoos, Martin Reck, Sara Brett
- Abstract
Loading... -
+
P1.01-58 - Comprehensive Serial Biomaterial Acquisition in Advanced NSCLC: Feasibility, Challenges and Perspectives
09:45 - 09:45 | Presenter: Marc Andre Schneider | Author(s): Sabine Wessels, Petros Christopoulos, Thomas Muley, Michael Meister, Ingrid Heinzmann-Groth, Arne Warth, Esther Herpel, Albrecht Stenzinger, Simone Hummler, Ursula Klingmueller, Jonas Kuon, Claus-Peter Heussel, Ralf Eberhardt, Felix Herth, Hauke Winter, Helge Bischoff, Martin Reck, Rudolf Maria Huber, Michael Thomas
- Abstract
Loading...
-
+
P1.18 - Treatment of Locoregional Disease - NSCLC
- 09:45 - 18:00
- 9/08/2019
- Location: Exhibit Hall
- Type: Poster Viewing in the Exhibit Hall
- Track: Treatment of Locoregional Disease - NSCLC
-
+
P1.18-01 - RELAY EU/US Subset: Ramucirumab Plus Erlotinib Improves Progression-Free Survival in First-Line EGFR Mutation-Positive NSCLC
09:45 - 09:45 | Presenter: Santiago Ponce Aix | Author(s): Silvia Novello, Edward Garon, Kazuhiko Nakagawa, Ernest Nadal, Denis Moro-Sibilot, Miriam Alonso Garcia, Elizabeth Fabre, Bente Frimodt-Moller, Annamaria Hayden Zimmermann, Carla M Visseren-Grul, Martin Reck
- Abstract
Loading... -
+
P1.18-02 - The AEGEAN Phase 3 Trial of Neoadjuvant/Adjuvant Durvalumab in Patients with Resectable Stage II/III NSCLC
09:45 - 09:45 | Presenter: John Victor Heymach | Author(s): Janis M Taube, Tetsuya Mitsudomi, David Harpole, Mike Aperghis, Leonardo Trani, Mark Powell, Phillip Dennis, Martin Reck
- Abstract
Loading...
-
+
P2.01 - Advanced NSCLC
- 10:15 - 18:15
- 9/09/2019
- Location: Exhibit Hall
- Type: Poster Viewing in the Exhibit Hall
- Track: Advanced NSCLC
-
+
P2.01-24 - CANOPY-2: Phase 3 Study of Canakinumab Plus Docetaxel as Second/Third Line Therapy in Locally Advanced/Metastatic NSCLC
10:15 - 10:15 | Presenter: Luis Paz-Ares | Author(s): Yasushi Goto, Darren WT Lim, Vassiliki A Papadimitrakopoulou, Bijoyesh Mookerjee, Isabelle Malet, Zhu Zewen, Martin Reck
- Abstract
Loading...
-
+
PR04 - Press Conference
- 10:45 - 11:30
- 9/10/2019
- Location: CC7.1 A&B
- Type: Press Conference
- Track:
-
+
PR04.02 - KEYNOTE-024 3-Year Survival Update: Pembrolizumab vs Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer
10:50 - 10:58
- Abstract
No abstract available for this presentation
-
+
OA14 - Update of Phase 3 Trials and the Role of HPD
- 11:30 - 13:00
- 9/10/2019
- Location: Vienna (2016)
- IASLC CME Accredited
- Type: Oral Session
- Track: Immuno-oncology
- Moderators:Julie R Brahmer, Diego Signorelli
-
+
OA14.01 - KEYNOTE-024 3-Year Survival Update: Pembrolizumab vs Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer
11:30 - 11:40 | Presenter: Martin Reck | Author(s): Delvys Rodríguez-Abreu, Andrew G. Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe, Mary O'Brien, Suman Rao, Katsuyuki Hotta, Tara Garay, Erin Jensen, Victoria Ebiana, Julie R. Brahmer
- Abstract
Loading...
-
+
PC04 - Is Chemotherapy Necessary for Advanced NSCLC Patients With PD-L1 50% or More?
- 11:30 - 13:00
- 9/10/2019
- Location: Copenhagen (1980)
- IASLC CME Accredited
- Type: Pro-Con Session
- Track: Advanced NSCLC
- Moderators:Margarita Majem, Carlos Carracedo Gonzales
-
+
PC04.02 - CON: ICI Is Enough
12:00 - 12:30 | Presenter: Martin Reck
- Abstract
Loading...